Skip to main content

Table 1 Demographic and clinical features of systemic sclerosis patients

From: Prognostic impact of coronary microcirculation abnormalities in systemic sclerosis: a prospective study to evaluate the role of non-invasive tests

  dcSSc lcSSc  
Demographic and clinical features Data Range Data range P-value
Number of patients 15 26  
Age (yrs; mean; SD) 53 ± 13.1 28 to 71 52 ± 9.3 39 to 73 NS
M/F ratio 2/13   6/20   NS
Disease duration (yrs; mean; SD) 8 ± 3.3 2 to 15 8.5 ± 5.8 1 to 21 NS
Clinical manifestation    
Raynaud phoenomenon 15 (100%) 23 (88%) NS
Teleangectasias 10 (66%) 9 (35%) NS
Lung involvement 13 (87%) 14 (54%) NS
Oesophagus involvement 14 (93%) 9 (35%) 0.001
Trophic ulcers 10 (66%) 8 (31%) 0.06
Calcinosis 0 5 (19%) NS
Serological findings    
Anti-Scl-70 12 (80%) 10 (38%) 0.02
Anti-Centromere 0 6 (23%) NS
Risk factor for CAD    
Hypertension 4 (27%) 9 (35%) NS
Diabetes 2 (13%) 2 (7%) NS
Hypercholesterolemia 6 (40%) 4 (15%) NS
Treatment    
D-Penicillamine 3 (19%) 5 (19%) NS
Cyclophosphamide 8 (50%) 0 0.0004
Cyclosporine 3 (19%) 3 (11%) NS
Iloprost 13 (87%) 9 (35%) 0.003
Steroids 6 (37%) 2 (7%) 0.004
Calcium-blockers 3 (19%) 1 (3%) NS
ACE-inhibitors 3 (19%) 1 (3%) NS
Angiotensin II receptor blocker 2 (13%) 1 (3%) NS